

## A Covid-19 Patient With Immune Thrombocytopenic Purpura


**Indranil Chatterjee<sup>1\*</sup>, Rakhi Bakuli<sup>2</sup>**<sup>1</sup>Assistant Professor, Birbhum Pharmacy School, Birbhum, West Bengal, India.<sup>2</sup>Assistant Professor, PG Institute of Medical Sciences, Chandrakona Town, Paschim Midnapore, West Bengal, India.**\*Corresponding Author:** Indranil Chatterjee, Assistant Professor, Birbhum Pharmacy School, Birbhum, West Bengal India. Email: indranil.chax@outlook.com**Received:** May 26, 2020**Published:** June 18, 2020© All rights are reserved by **Indranil Chatterjee, Rakhi Bakuli.**

A 65-year-elderly person with hypertension, immune system hypothyroidism, and known Covid-19 presentation introduced to the crisis division with a 4-day history of weakness, fever, dry hack and stomach uneasiness. She was afebrile and had a respiratory pace of 28 breaths for every moment and an oxygen immersion of 89% while she was breathing encompassing air; breath sounds were decreased respectively with bibasilar rales. The stomach assessment was ordinary. Research center tests demonstrated an ordinary white-cell check, hemoglobin level (14.2g per deciliter) and platelet tally (183,000 for each cubic millimeter). The C-receptive protein level was raised at 55 mg for each liter, and liver-work tests indicated cholestasis. An oropharyngeal swab for Covid-19 testing was certain. Chest processed tomography (CT) demonstrated ground-glass opacities in the lower zones. The patient was conceded and started to get treatment with intravenous amoxicillin clavulanic corrosive, low-atomic weight heparin, and oxygen.

On day 4, lower-limit purpura (Figure 1) showed up and epistaxis happened. Detached thrombocytopenia (platelet check, 66,000 for every cubic millimeter) was noticed; these discoveries provoked end of heparin and anti-microbials.

On day 5, the platelet tally was 16,000 for each cubic millimeter, and on day 7, it was 8000 for every cubic millimeter. The prothrombin and enacted fractional thromboplastin times were typical; the fibrinogen level was 5g for every liter (ordinary range, 2 to 4).

A fringe blood smear indicated under 1% schistocytes. The degree of thyroid peroxidase antibodies was 245 U for each milliliter (ordinary worth, < 35); antiplatelet factor 4, antiplatelet antibodies and antinuclear antibodies were not distinguished. Intravenous safe globulin was regulated at a pace of 1g for every kilogram of body weight. Following 48 hours, the platelet tally diminished to 1000 for each cubic millimeter and the purpuric injuries advanced; this incited a second imbue of safe globulin at a portion of 1g for each kilogram [1,2]. Bone marrow yearning demonstrated ordinary cellularity with an expansion in pleomorphic megakaryo-

**Figure 1:** Purpuric Lesions on the Covid-19 Patient.

cytes. Erythroblast and granulocyte cell lines were ordinary, without proof of trim phagocytosis.

On day 9, a correct frontal cerebral pain created in the patient, without fever, heaving, or central neurologic deficiency. CT of the head indicated a subarachnoid microhemorrhage in the correct frontal flap. The platelet tally was 2000 for each cubic millimeter, and a platelet transfusion was managed with 100 mg of prednisolone; eltrombopag (75 mg for every day) was initiated [1,2].

On day 10, the cerebral pain had settled, there were no new neurologic discoveries, and the platelet tally had expanded to 10,000 for each cubic millimeter. The various lab tests had standardized with the exception of the fibrinogen level, which stayed raised (3.5g per liter).

On day 13, the platelet check was 139,000 for every cubic millimeter, and the purpura had vanished. The worldly arrangement for this situation suggests [3], however doesn't demonstrate, that Covid-19 was a causal factor in safe thrombocytopenia in this patient. Luckily, she had a reaction to treatment, but in a deferred de-

sign. In spite of the fact that the cerebral draining didn't have major sequelae, this case shows they should be cautious for intricacies related with Covid-19.

### Acknowledgement

We would like to express our sincere thanks to Prof. D.K Sarkar, Prof and HOD, Pharmacology of Medical College Kolkata, 88, College St, College Square, Kolkata, West Bengal- 700073, India, for sharing the case report and medical condition with us. Based on these data and reports this communication has been made.

### Bibliography

1. Neunert C., *et al.* "American Society of Hematology 2019 guidelines for immune thrombocytopenia". *Blood Advances* 3.23 (2019): 3829-3866.
2. Provan D., *et al.* "Updated international consensus report on the investigation and management of primary immune thrombocytopenia". *Blood Advances* 3.22 (2019): 3780-3817.
3. Lippi G., *et al.* "Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis". *Clinica Chimica Acta* 506 (2020): 145-148.

#### Assets from publication with us

- Prompt Acknowledgement after receiving the article
- Thorough Double blinded peer review
- Rapid Publication
- Issue of Publication Certificate
- High visibility of your Published work

**Website:** <https://www.actascientific.com/>

**Submit Article:** <https://www.actascientific.com/submission.php>

**Email us:** [editor@actascientific.com](mailto:editor@actascientific.com)

**Contact us:** +91 9182824667